Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Germany(1,344/week)
    • Poland(1,165/week)
    • France(808/week)
    • Spain(798/week)
    • Czechia(471/week)
    • View all (8,216/week)
  • News
    • United States(422/week)
    • Manufacturing(322/week)
    • Technology(335/week)
    • Energy(221/week)
    • Other Manufacturing(282/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

Eli Lilly and Company

Feb 25, 2021
Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions
Feb 24, 2021
Lilly to Participate in Cowen Health Care Conference
Feb 18, 2021
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
Feb 17, 2021
Kimberly H. Johnson Elected to Lilly Board of Directors
Feb 17, 2021
Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
Feb 11, 2021
Iterative Scopes Announces Partnership with Eli Lilly and Company to Advance AI Applications for Inflammatory Bowel Disease (IBD) Clinical Trials
Feb 09, 2021
Lilly Appoints Anat Ashkenazi Chief Financial Officer
Feb 04, 2021
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference
Feb 03, 2021
Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
Feb 01, 2021
Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients
Jan 29, 2021
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results
Jan 28, 2021
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
Jan 28, 2021
Lilly, Life for a Child and Beyond Type 1 advance partnership to improve diabetes care in resource-limited countries
Jan 26, 2021
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent
Jan 22, 2021
Lilly Completes Acquisition of Prevail Therapeutics
Jan 21, 2021
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Jan 19, 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Jan 15, 2021
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund
Jan 15, 2021
Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement
Jan 14, 2021
Gabrielle Sulzberger Elected to Lilly Board of Directors
  •  
  • Page 1
  • ››

Latest News

May 29, 2023

GIGABYTE’s AI Servers with Superchips Shine at COMPUTEX, Redefining a New Era of Computing

May 29, 2023

Phison Showcases Pioneering Storage Solutions and High-Speed Transmission at Computex 2023

May 29, 2023

Mitsubishi Electric and Mitsubishi Heavy Industries Definitively Agree to Integrate Their Power-generator...

May 29, 2023

Boeing and ST Engineering Sign P-8 Sustainment MoU

May 29, 2023

North Korea informs Japan of upcoming 'satellite launch'

May 29, 2023

North Korea announces 'satellite' launch: Japan

May 28, 2023

Israeli strikes on Damascus: Syrian state media

May 28, 2023

EU, NATO congratulate Erdogan on Turkey re-election

View all News

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2023 EPICOS
Made by Wedia